PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Roger S. Newton, Ph.D., Esperion’s executive chairman, chief scientific officer and company founder, will present at the Stifel Nicolaus 2013 Healthcare Conference in Boston. Dr. Newton’s presentation will take place on Wednesday, September 11, at 3:50 p.m. ET at the Four Seasons Hotel.

To hear the live audio webcast and view the slides of the Esperion presentation, please visit http://www.veracast.com/webcasts/stifel/healthcare2013/28113409462.cfm. A replay of the webcast will be available on the company’s website for 30 days following the live event.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002, Esperion’s lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and expects to initiate a robust Phase 2b clinical program in the fourth quarter of 2013. For more information, please visit www.esperion.com.